Gene expression profiles discriminate between pathological complete response and resistance to neoadjuvant FEC100 in breast cancer

Cancer Genomics and Proteomics

Volumn 3, Issue 2, 2006, Pages 89-95

  Millour, Marie ^a,b   Charbonnel, Catherine ^a,c   Magrangeas, Florence ^c,d   Minvielle, Stéphane ^c,d   Campion, Loïc ^a   Gouraud, Wilfried ^a,c   Campone, Mario ^a   Déporte Féty, Régine ^a   Bignon, Yves Jean ^b   Penault Llorca, Frédérique ^e   Jézéquel, Pascal ^a,c  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b CENTRE JEAN PERRIN   (France)

^c CHU de Nantes   (France)

^d INSTITUT DE BIOLOGIE   (France)

^e INSERM   (France)

Author keywords

Breast cancer; Drug resistance; Epirubicin and cyclophosphamide chemotherapy; Gene expression profiles; Neoadjuvant fluorouracil

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; FEC 100; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; DRUG TOLERANCE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY;

EID: 33646000280     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Charfare H, Limongelli S and Purushotam AD: Neoadjuvant chemotherapy in breast cancer. Br J Surg 92: 14-23, 2005.
2. Ling V: Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40 Suppl: S3-8, 1997.
3. Bonneterre J, Roche H, Kerbrat P, Bremond A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P and Chapelle-Marcillac I: Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23: 2686-2693, 2005.
4. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D and Brown PO: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235, 2000.
5. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y and Yamori T: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62: 2239-2247, 2002.
6. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR and Polak K: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6: 17-32, 2004.
7. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez C, Elledge R, Moshin S, Osborne CK, Chamness GC, Allred DC and O'Connell P: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369, 2003.
8. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S and Kato K: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23: 422-431, 2005.
9. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S and van de Vijver MJ: Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23: 3331-3342, 2005.
10. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN and Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685, 2005.
11. Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, Bertucci F, Birnbaum D, Nguyen C, Harousseau JL, Bataille R, Houlgatte R and Minvielle S: Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101: 4998-5006, 2003.
12. Stekel D: Analysis of differentially expressed genes. In: Microarray Bioinformatics, first edition. Cambridge University Press, Cambridge, pp. 110-138, 2003.
13. Michiels S, Koscielny S and Hill C: Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365: 488-492, 2005.
14. Stekel D: Analysis of relationships between genes, tissues or treatments. In: Microarray Bioinformatics, first edition. Cambridge University Press, Cambridge, pp. 139-182, 2003.
15. Saraste M: Oxidative phosphorylation at the fin de siecle. Science 283: 1482-1488, 1999.
16. Muller I, Niethammer D and Bruchelt G: Anthracyclines-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int J Mol Med 1: 491-494, 1998.
17. Davies KJA and Doroshow JH: Redox cycling of anthracyclines by cardiac mitochondria. J Biol Chem 261: 3060-3067, 1986.
18. Wong TW, Yu HY, Kong SK, Fung KP and Kwok TT: The decrease of mitochondrial NADH dehydrogenase and drug induced apoptosis in doxorubicin resistant A431 cells. Life Sci 67: 1111-1118, 2000.
19. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA and Robinson JP: Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278: 8516-8525, 2003.
20. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zemutsu H, Katagiri T, Yamazaki K, Nakamura Y and Yamori T: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62: 1139-1147, 2002.
21. Ichikawa Y, Hirokawa M, Aiba N, Fujishima N, Komatsuda A, Saitoh H, Kume M, Miura I and Sawada K: Monitoring the expression profiles of doxorubicin-resistant K562 leukemia cells by serial analysis of gene expression. Int J Hematol 79: 276-282, 2004.
22. DeHaan C, Habibi-Nazhad B, Yan E, Salloum N, Parliament M and Allalunis-Turner J: Mutation in mitochondrial complex I ND6 subunit is associated with defective response to hypoxia in human glioma cells. Mol Cancer 3: 1-19, 2004.